
US-based firm Organon and Danish upstart Cirqle Biomedical, which is focused on women’s health, have inked a partnership and exclusive licensing agreement for a new, non-hormonal contraceptive candidate, the two firms announce in a joint press release.
Cirqle Biomedical is trying to create a non-hormonal contraceptive for women, and the idea behind the project is ”to create a temporary barrier to sperm transport by topically reinforcing the existing cervical mucus barrier,” Cirqle writes, noting that preclinical research seems to support the method.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app